| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8228481 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 9 Pages |
Abstract
Three months of triplet ICT followed by gemcitabine-based CCRT is feasible, moderately active, and associated with encouraging survival in patients with LAPC.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Hui-Ju M.D., Yu-Lin M.D., Hsiu-Po M.D., Yen-Feng Ph.D., Ming-Chu M.D., Ph.D., Chih-Hung M.D., Ph.D., Yu-Wen M.D., Ph.D., Jen-Shi M.D., Ruey-Kuen M.D., Pin-Wen M.D., Yan-Shen M.D., Ph.D., Ann-Lii M.D., Ph.D., Jang-Yang M.D., Jacqueline M.D.,